Tenet has ‘outstanding’ 2024, addresses policy changes in Washington
Health system leaders said Tenet is mostly insulated from proposed policy changes like Medicaid cuts due to its focus on ambulatory surgical centers.
CVS slashes profit in 2024 as high medical costs hit Aetna
However, the healthcare giant beat Wall Street expectations in earnings and revenue in the fourth quarter, sending CVS stock soaring Wednesday.
Trump orders agencies to plan for ‘large-scale’ job cuts
While Trump’s executive order provides substantial power to Elon Musk’s DOGE effort, it’s not specifically targeted to health agencies like the FDA.
Trump administration healthcare executive orders hit snags in court
Although the directives to limit publicly available healthcare data and cut federal funding for medical research have been temporarily blocked by federal judges, providers face uncertainty as they await final rulings.
Large healthcare companies are redistributing most of their profits to shareholders, study finds
Researchers suggested that policymakers encourage reinvestment of capital into patient care and limit share buybacks based on the findings.
Nearly two-thirds of Medicaid beneficiaries already work: KFF
Most adults on Medicaid are already employed, suggesting few beneficiaries wouldn’t meet a work requirement policy being considered by Republicans in Congress.
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?
Kaiser’s 2024 earnings show ROI of Risant Health spinoff
Risant Health acquisitions accounted for about half of Kaiser’s net income in 2024.
Humana’s 2024 profit slashed in half amid higher medical spending
The massive insurer now expects to lose 550,000 Medicare Advantage members — roughly one-tenth of its individual MA footprint — this year as a result of plan cuts.
Former FDA head Gottlieb calls for less regulation of certain AI tools
Scott Gottlieb supports a reversion to an earlier interpretation of the 21st Century Cures Act, which would exempt more types of clinical decision support software from the FDA’s premarket review process.